In this phase 3 double-blind, randomized controlled trial, patients with PIK3CA mutated hormone receptor-positive, HER2-negative breast cancers who relapsed either during or within 1 year of completing adjuvant endocrine therapy were randomized to receive either inavolisib or placebo in combination with palbociclib and fulvestrant. Here, ERBB2 is linked to breast carcinoma.